Plasma ghrelin and gastric pacing in morbidly obese patients.

Gastric pacing is a new treatment of morbid obesity. Patients experience increased satiety, the ability to reduce food intake, and a resultant weight loss. We hypothesized that the appetite-stimulating hormone ghrelin is involved in the changed appetite and eating behavior resulting from gastric pacing.

Long-term follow-up of gastric stimulation for obesity: the Mestre 8-year experience.

Background: 10 years experience with gastric stimulation demonstrates promise, in particular because weight loss is achieved and maintained without drugs or side-effects. We report on a total of 65 patients who have received an Implantable Gastric Stimulator (IGS(R)) since 1995.

Methods: 65 patients have received an IGS and were monitored for weight loss as well as co-morbidities.

Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin.

Objective: A gastric pacemaker has been developed to treat morbid obesity. Patients experience increased satiety, the ability to reduce food intake, and a resultant weight loss. However, the mechanism behind the changed eating behavior in paced patients is still under investigation.

Gastric pacing as therapy for morbid obesity: preliminary results.

Background: A novel method to treat morbid obesity is presented--gastric electrical pacing. Following animal research, human investigation in a total of 24 patients in three cohorts began in 1995.

Methods: Morbidly obese subjects (BMI > or = 40) received electrical stimulation devices in 1995/6 (n = 4), 1998 (n = 10) and 2000 (n = 10).

Long-term Effects of Gastric Pacing to Reduce Feed Intake in Swine.

BACKGROUND: The purpose of this study was to show the effect of chronic antral gastric electrical stimulation on the feeding behavior of swine. METHODS: Three groups of swine were investigated; first group control-group, second group- 8 months of electrical antral stimulation (10 Volts; 450 micros; Hertz 100; Mode: Cycling; on time 3.25 s; off time 5.